Citrobacter rodentium is a Gram-negative, murine-specific enteric pathogen that infects epithelial cells in the colon. It is closely related to the clinically relevant human pathogen, enterohemorrhagic Escherichia coli (EHEC), a leading cause of haemorrhagic colitis and haemolytic uremic syndrome. We have previously reported that a novel antimicrobial peptide, wrwycr, compromises bacterial DNA repair and significantly reduces the survival of acid-stressed EHEC, suggesting an antimicrobial strategy for targeting the survival of ingested EHEC. This study examines the impact of peptide pretreatment on survival of the closely related murine pathogen, C. rodentium, before and after acid stress, using both in vitro and in vivo investigations. Peptide pretreatment of C. rodentium significantly and dramatically increases acid-stress-induced killing in a peptide-dosedependent and time-dependent manner. Reduction in survival rates after brief pretreatment with peptide (25-65 µM) followed by 1 h at pH 3.5 ranges from 6 to 8 log fold relative to untreated C. rodentium, with no detectable bacteria after 65 µM peptide-acid treatment. Using a C57BL/6 mouse model of infection, peptide pretreatment of C. rodentium with wrwycr prior to orogastric gavage eliminates evidence of infection based on C. rodentium colonization levels, faecal scores, colonic histology, faecal microbiome and visual observation of overall animal health. These findings provide compelling evidence for the role of the peptide wrwycr as a potential strategy to control the growth and colonization of enteric pathogens.
INTRODUCTION
Enterohemorrhagic Escherichia coli (EHEC) is a Gramnegative noninvasive food-borne pathogen whose infection is associated with abdominal cramps, bloody diarrhoea and haemorrhagic colitis that can progress to a serious and sometimes fatal systemic disease, haemolytic uremic syndrome (HUS) (Etienne-Mesmin et al., 2011; Rodrigues et al., 2012) . EHEC O157 : H7 is the serotype most commonly linked to human infection and outbreaks occur across the globe, contributing to over 75 000 human infections and 60 deaths per year (Bavaro, 2009; House et al., 2009 ).
Prevention and treatment options for EHEC infection are limited. In 2008, Bioniche Life Sciences released a cattle vaccine against EHEC O157, which targets the pathogen at the source and is aimed at preventing transmission of E. coli O157 : H7 from cattle to humans (McNeilly et al., 2010) . While this vaccine holds promise for reducing the risk of infection, there is still a significant number of cases of human infection leading to outbreaks globally (Cox et al., 2014) . Treatment of EHEC infection is currently limited to intravenous fluid volume expansion and supportive therapy (Ardissino et al., 2016; Cornfield, 2016) . The most common form of treatment for bacterial infection, antibiotics, is not recommended for EHEC infection since studies report that some antibiotics stimulate increased circulating toxins that can increase the risk of HUS (Cox et al., 2014) . Due to the ineffectiveness of traditional treatments, there has been increased interest in the development of new treatment strategies. Amongst these are several forms of antibody therapy, plasmapheresis, zinc-based salts, small peptide molecules and probiotics (Crane et al., 2011; Dolgin, 2011; Laursen, 2011; Rodrigues et al., 2012) . While many of these treatment strategies show promise, recent outbreaks of EHEC infection have now led to an interest in the development of preventative strategies that target the pathogen before it is able to colonize the intestine (Dolgin, 2011) .
Prior to colonization of the human large intestine, EHEC must survive environmental stresses encountered in the stomach and upper gastrointestinal (GI) tract (Thorpe, 2004) . The most common and severe type of stress is the extreme acidity in the stomach, followed by weak acid stress in the upper GI tract (Lin et al., 1996; Lino et al., 2011; Thorpe, 2004) .
The extreme acidic environment of the stomach acts as one of the human body's natural defence mechanisms against ingested pathogens, causing extensive DNA damage that can result in lethal consequences for the pathogen, if left unrepaired (Kunkel, 1984) . A vital aspect of DNA damage repair is the formation of intermediate structures called Holliday junctions (HJs) . These intermediate structures must be fully resolved in order for DNA repair to proceed. Failure to resolve these structures is lethal to the bacteria (Lino et al., 2011) . If acid-induced DNA damage repair is ablated through inhibition of HJ resolution, this would compromise EHEC survival and thereby decrease the potential for EHEC infection of the GI tract.
Previous studies by Segall's laboratory have identified and characterized several hexapeptides that target HJs (Gunderson et al., 2009) . The peptide of particular interest to this study is the D-isomer of a 6-amino acid peptide, wrwycr (Boldt et al., 2004; Gunderson & Segall, 2006; Kepple et al., 2005) . In its active form, wrwycr is a dimer linked by a disulphide bridge. This peptide is able to inhibit mechanisms of DNA damage repair and recombination that proceed through HJ intermediates (Gunderson et al., 2009; Kepple et al., 2008) . Specifically, the peptide dimer binds to four-arm HJs and, to a lesser degree, three-arm DNA structures that mimic replication forks, thereby permitting the peptide to inhibit several structurally and mechanistically unrelated proteins that process HJs (Kepple et al., 2005 (Kepple et al., , 2008 . More recent studies have expanded the list of potential intrabacterial targets of the peptide, based on how bacterial cells respond to peptide treatment. It is clear that the peptide in some way causes cells to phenotypically starve for iron and to damage the cell membrane in ways that lead to the induction of the envelope stress response (Orchard et al., 2012) . Many of the effects of the peptide are similar to those of a small molecule, TPI1609-10 (Yitzhaki et al., 2012 . Consequently, wrwycr is a potent, broad-spectrum antimicrobial able to inhibit bacterial growth in a dose-dependent manner with both intracellular and membrane targets (Gunderson & Segall, 2006; Lino et al., 2011; Su et al., 2010) .
We previously demonstrated that pretreatment of EHEC with wrwycr followed by acid stress similar to that of gastric acid profoundly decreases the survival of EHEC seropathotypes that are highly associated with HUS (Lino et al., 2011) . Furthermore, acid-induced EHEC killing was dose dependent with peptide concentration.
These results suggest a model for a potential prevention strategy for EHEC infection in humans. Since the Lino et al. (2011) studies were performed in vitro, testing with a suitable in vivo model of EHEC infection is necessary in order to further explore the potential of this peptide as a preventative antimicrobial. EHEC O157 : H7 is a human-specific pathogen and therefore does not readily colonize the mouse GI tract, without changes to the host that compromise the physiological relevance. A well-established mouse model of EHEC infection employs the murine-specific pathogen Citrobacter rodentium (Rodrigues et al., 2012; Smith & Bhagwat, 2013) . C. rodentium is a Gram-negative pathogen that readily colonizes the mouse colon, causing colitis. Similar to EHEC, C. rodentium contains the type III secretion system and the locus of enterocyte effacement pathogenicity island that encodes various effector proteins and virulence factors that are critical to the pathogenic mechanism (Collins et al., 2014; Gareau et al., 2011) . Previous studies have shown that C. rodentium infection produces colonic inflammation, soft stools and loss of gut barrier integrity, with colonic hyperplasia being the main hallmark of infection. Similarly, EHEC infections in humans can result in bouts of diarrhoea and colonic inflammation, resulting in thickening of the intestinal cell wall as seen in murine colonic hyperplasia (Collins et al., 2014) . Although the symptoms of EHEC O157 : H7 infection vary according to the severity of disease, the similarity in virulence factors make C. rodentium a suitable animal model to study EHEC O157 : H7 infection.
The primary aim of this study was to explore the potential of the novel antimicrobial peptide wrwycr as a preventative strategy for reducing EHEC infection in a C. rodentium mouse infection model. Our first objective was to use in vitro studies to evaluate the effect of peptide pretreatment on the survival of acid-stressed C. rodentium and to determine the peptide dose and time dependencies of the response. The second objective was to evaluate the efficacy of peptide pretreatment on C. rodentium infection in vivo. Analyses of faecal microbial communities, colonic crypt hyperplasia and overall health and well-being were used to delineate changes after infection with C. rodentium. To our knowledge, these findings provide the first evidence that pretreatment of C. rodentium with the antimicrobial wrwycr alters the course of enteric infection and, thus, offers an exciting potential for a novel antimicrobial prevention strategy.
METHODS
Bacterial strains. C. rodentium, strain DBS 100 (kindly provided by the late David Schauer, Massachusetts Institute of Technology), was used for in vitro and in vivo infection studies (Rodrigues et al., 2012) . Bacterial glycerol stocks were maintained at À80 C and were streaked onto Luria-Bertani (LB) (BioShop) agar prior to use in order to obtain single colonies. Overnight cultures were prepared by inoculating single colonies into LB broth, which was incubated at 37 C with shaking.
Antimicrobial peptide wrwycr. The peptide wrwycr was synthesized with a C-terminal amide group, purified to >95 % purity at SigmaGenosys or Biosynthesis and dissolved in 50 % dimethyl sulphoxide (DMSO), as described previously (Gunderson & Segall, 2006) . A wrwycr stock solution (10 mM) was maintained at À20 C in 50 or 100 % DMSO and the degree of dimerization was checked by HPLC, as described previously (Orchard et al., 2012) . The stock used comprised at least 85 % dimerized wrwycr; for ease, however, concentrations are expressed as if the solution was composed of monomer.
In vitro survival assays. Individual C. rodentium colonies were removed from LB plates, inoculated into 10 ml LB and cultured at 37 C with shaking overnight. Prior to use, the overnight bacterial cultures were diluted 1 : 10 in fresh LB broth and grown 1-2 h at 37 C with shaking to mid-exponential phase (OD 600 0.4-0.6). For the evaluation of C. rodentium survival after exposure to acid, bacteria were pelleted at 3500 r.p.m. (903 g) for 10 min at 4 C, resuspended in LB broth at either pH 7.0 or pH 3.5 (adjusted with HCl) and then incubated at 37 C for 3 h.
For the determination of C. rodentium survival after peptide treatment, bacteria were pelleted as mentioned above and resuspended in 0.5Â phosphate-buffered saline (PBS) (68.5 mM NaCl, 1.35 mM KCl, 5 mM Na 2 HPO 4 , 0.9 mM KH 2 PO 4 ) containing either 0, 25, 50 or 65 µM of peptide wrwycr. Resuspended bacteria were then incubated for 1 h at room temperature. Samples (10 µl) were taken at t=0, 15, 30, 45 and 60 min; serially diluted in 1Â PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 ); plated onto LB agar and grown overnight at 37 C.
To evaluate C. rodentium survival after peptide pretreatment followed by acute acid treatment, bacteria were pelleted as mentioned above and resuspended in 0.5Â PBS containing either 0, 25, 50 or 65 µM of peptide wrwycr. Resuspended bacteria were incubated for 15 min at room temperature and then pelleted as mentioned above. Bacterial pellets were then resuspended in PBS at pH 3.5 and incubated at 37 C for 1 h. Samples were taken at t=UT (untreated; immediately prior to addition of peptide), 0 (immediately prior to addition of acid), 15, 30, 45 and 60 min; serially diluted in 1Â PBS; plated onto LB agar and grown overnight at 37 C.
Biofilm treatment and survival assays. We also determined the effect of peptide and peptide-acid treatment on established C. rodentium biofilms. Biofilms were formed by inoculating 1 ml of a 1 : 1000 dilution of overnight cultures in fresh LB broth into 12-well plates (Greiner BioOne). Plates were incubated at 37 C under static growth conditions for 48 h, with 1 ml fresh LB broth being replaced every 12-16 h. Once the biofilms were formed, the medium was removed and washed twice with 1Â PBS. An equal volume of 0.5Â PBS containing the appropriate concentration of peptide was then added to each well and incubated at room temperature for 5 min. PBS was then removed, replaced with an equal volume of PBS at pH 3.5 and incubated at room temperature for 1 h. After incubation, wells were washed once with 1Â PBS and bacteria were scraped off the bottom of each well and suspended in 1Â PBS. Bacterial cell viability was assessed by preparing serial dilutions in 1Â PBS and plating onto LB agar overnight at 37 C.
Growth recovery after peptide and peptide-acid treatment assays. We also tested the ability of C. rodentium to recover from either peptide or peptide-acid treatment. To assess the ability of C. rodentium to recover from peptide treatment, overnight cultures were diluted to an OD 600 of 0.05 in Mueller Hinton Broth (MHB) (Sigma Aldrich) containing 0, 25, 50 or 65 µM peptide. MHB broth was used as a minimal media to allow efficient uptake of the peptide by the bacteria while still providing a sufficient source of nutrients. Diluted bacteria were then incubated statically for 50 h at 37 C. Samples were taken every 5 h, serially diluted in 1Â PBS and plated onto LB agar overnight at 37 C.
In order to assess the ability of C. rodentium to recover from peptideacid treatment, overnight cultures were diluted 1 : 10 in fresh LB broth and grown 1-2 h at 37 C with shaking to mid-exponential phase (OD 600 0.4-0.6). Bacteria were pretreated with 25-65 µM peptide followed by 1 h acid stress (pH 3.5), as described above. Following the peptide-acid treatment, bacteria were pelleted, as described above, and resuspended in an equal volume of MHB broth and incubated statically for 5 h at 37 C. Samples were taken every hour, serially diluted in 1Â PBS and plated onto LB agar overnight at 37 C.
Resistance assays. In order to assess the impact of a second peptide treatment of C. rodentium that has been pretreated with peptide, overnight cultures were diluted to an OD 600 of 0.05 in MHB broth containing 0, 25, 50 or 65 µM peptide. Bacteria were then incubated statically for 24 h at 37 C. Treated bacteria were then pelleted, as described above, and resuspended in an equal volume of 0.5Â PBS containing 50 µM peptide. Resuspended bacteria were incubated statically for 1 h at room temperature. Samples were taken after the initial 24 h of pretreatment and, following the 1 h of treatment in fresh peptide, serially diluted in 1Â PBS and plated onto LB agar overnight at 37 C.
Mouse infection model. Six-week-old female C57BL/6 mice (Jackson Laboratory) were used for in vivo studies. Mice were given free access to sterile drinking water and chow for the duration of the study. To assess the safety and efficacy of the peptide, animals were administered either peptide wrwycr or placebo wkhyny alone at the three concentrations (25, 50 or 65 µM; total volume=100 µl) via orogastric gavage (approximately 1.39, 2.70 and 3.61 µM peptide per gram mouse, respectively).
For the evaluation of peptide efficacy in vivo, mice were divided into six experimental groups: (1) sham-challenged mice, (2) mice infected with C. rodentium (10 8 c.f.u.), (3) mice administered placebo wkhyny (25, 50, 65 µM), (4) mice administered peptide wrwycr (25, 50, 65 µM), (5) mice infected with C. rodentium pretreated with placebo wkhyny (25, 50, 65 µM) and (6) mice infected with C. rodentium pretreated with peptide wrwycr (25, 50, 65 µM). All treatments were 100 µl in volume and mice were administered treatments by orogastric gavage as previously described (Gareau et al., 2011; Rodrigues et al., 2012) . For the groups 5 and 6, C. rodentium was pretreated with either peptide (25, 50, 65 µM) or placebo (25, 50, 65 µM) for 5 min at room temperature prior to orogastric gavage of the mice. Since our in vitro studies indicated that peptide pretreatment at all doses tested results in a decrease in survival, even within the 5 min pretreatment time, the infection dose of C. rodentium was standardized to 10 8 c.f.u. after peptide pretreatment as determined by plate count assay.
Mice were observed daily for overall health and well-being throughout the duration of the study protocol. The presence of fur ruffling, diarrhoea, lethargy and changes in weight were used as indicators of ill health (Gareau et al., 2011; Rodrigues et al., 2012) . Faecal samples were collected throughout the study period on days 0, 6 and 10 postinfection (PI) and stored at À80 o C for bacterial counts and quantitative PCR (qPCR) analysis. Mice were sacrificed on day 10 PI by administering 15 % CO 2 followed by cervical dislocation. Previous studies have shown that peak of infection occurs reproducibly 10 days PI with the hallmark signs of crypt hyperplasia and colonic mucosal thickening (Collins et al., 2014; Johnson-Henry et al., 2005) . After sacrifice, sections of distal colon were excised and placed into neutral-buffered formalin for histological analysis. All procedures and protocols were approved by the Animal Care Committee at the Hospital for Sick Children.
C. rodentium colonization. Faecal pellets were collected at day 10 PI and relative numbers of C. rodentium were measured using qPCR to probe for the presence of the espB gene of C. rodentium as previously described (Livak & Schmittgen, 2001; McKeel et al., 2002) . Briefly, faecal pellets were collected and stored at À80 C. Bacterial DNA was extracted using the QIAamp DNA Stool Kit (Qiagen). The concentration and purity (A 260 /A 280 ) of isolated DNA was measured using a Nanodrop 2000c spectrophotometer and isolated DNA was diluted to 5 ng ml À1 and frozen at À20 C. qPCR was performed using SsoFast EvaGreen supermix and a CFX96 C1000 Thermal Cycler (BioRad). C. rodentium was quantified relative to total bacteria using previously published primers specific to espB (Table S1 , available in the online Supplementary Material) (Livak & Schmittgen, 2001; McKeel et al., 2002) .
Histological analysis of colon samples. Colonic epithelial hyperplasia in response to C. rodentium infection with or without peptide pretreatment was evaluated on coded segments of distal colon, as described previously (Rodrigues et al., 2012) . Briefly, distal colon sections were excised at the time of sacrifice, fixed in 10 % neutral-buffered formalin and embedded in paraffin. Sections were stained with haematoxylin and eosin and visualized using a Leica DM5000B microscope, Leica DFC350 FX camera and ImageJ software. Crypt cell lengths were measured on coded segments, with findings presented as the mean of 10 crypts per section from three nonadjacent sections.
Analysis of faecal microbiota composition. The faecal microbiota was analysed using 16S rRNA qPCR analysis. Briefly, faecal pellets were collected and stored at À80 C. Bacterial DNA was extracted using the QIAamp DNA Stool Kit. The concentration and purity (A 260 /A 280 ) of isolated DNA was measured using a Nanodrop 2000c spectrophotometer. Isolated DNA was diluted to 5 ng ml À1 and frozen at À20 C. qPCR was performed using SsoFast EvaGreen supermix and a CFX96 C1000 Thermal Cycler. Bacteroidetes, Firmicutes, Gammaproteobacteria and Lactobacillus were quantified relative to total bacteria by using previously published primers (Table S1 ) (Bacchetti De Gregoris et al., 2011) . Data analyses were performed, as described previously (Livak & Schmittgen, 2001; Pfaffl, 2001 ). To avoid false-positive test results, cycle threshold values >30 were not included in the analysis. Comparisons were made between the control group and the experimental groups.
Statistical analyses. Results are expressed as the mean of three individual experiments, ±standard error of the means (SEM). Statistical analyses were performed using Student's t-test, Mann-Whitney test or two-way analysis of variance (ANOVA), with Tukey's multiple comparisons testing to determine significance between experimental conditions. P values <0.05 were considered statistically significant.
RESULTS

Survival of C. rodentium after either acid or peptide treatment
Survival assays of C. rodentium at acidic versus neutral pH values showed a significant 2-3 log fold decrease in C. rodentium viability at pH 3.5 for 2-3 h treatment time and a 1 log fold decrease over a 1 h treatment time (P<0.05) (Fig. 1a) . Initial survival assays over a range from pH 7 to 3.5 indicated maximum viability loss at pH 3.5, which is the reported pH of murine gastric acid (McConnell et al., 2008) (Fig. S1 ). These results indicate that C. rodentium is sensitive to acid in a time-and pH-dependent manner.
When C. rodentium was treated with peptide wrwycr alone, there was a significant time-and dose-dependent decrease in bacterial viability over the course of a 60 min treatment (P<0.05). Viability losses ranged from 1 to 4 log fold for peptide concentrations of 25-65 µM relative to PBS-treated controls over the 60 min time course (Fig. 1b) . This loss of viability was only evident for planktonic C. rodentium and not for established C. rodentium biofilms (Fig. 1c) . Results were the same for C. rodentium grown to either lag phase, log phase or stationary phase. For the remainder of the experiments, C. rodentium was grown to mid-log phase since virulence factor expression in C. rodentium has been shown to be optimally expressed at this growth phase (Rosenshine et al., 1996) . These results show that C. rodentium is sensitive to peptide treatment with losses in viability similar to those previously reported for the human enteric pathogen, EHEC O157 : H7 (Lino et al., 2011) .
Peptide wrwycr pretreatment enhances acidinduced killing of C. rodentium When C. rodentium was pretreated with peptide for 15 min and then incubated at pH 3.5, there was a dose-and timedependent decrease in viability over the course of the 60 min acid treatment (Fig. 1d) . Reductions in viability compared with untreated C. rodentium ranged from 6 log fold to below detectable limits (10 2 c.f.u.), with no viable C. rodentium detected after 65 µM peptide pretreatment followed by 60 min of acid stress. Compared to the 1 log fold decrease in survival for 10 8 c.f.u. C. rodentium after 1 h of acid stress alone (Fig. 1a) , peptide pretreatment enhanced survival loss over acid stress alone by 5 log fold. Relative to peptide treatment alone, the peptide-acid treatment enhanced survival loss by 2-4 log fold, depending on the peptide concentration. These results demonstrate that survival after peptide-acid treatment is significantly lower than survival after either peptide or acid treatment alone and that survival is dependent on both peptide concentration and treatment time.
Growth recovery of peptide-pretreated C. rodentium
We next evaluated growth recovery of C. rodentium treated with either peptide alone or pretreated with peptide followed by acid treatment and then grown in MHB to permit recovery. For C. rodentium treated with peptide alone (25/50/65 µM), there was an expected decrease in survival in the first 10 h, with evidence of partial to full recovery over the course of 50 h (Fig. 2a) . C. rodentium growth was either fully recovered (25 µM peptide) to the level of the control group or partially recovered (with 50 or 65 µM peptide). After 1 week, all peptide only treatment samples showed full recovery.
When C. rodentium was pretreated with 25-65 µM peptide followed by 1 h acid stress, growth recovery was dramatically reduced with no growth recovery detected for 50-65 µM peptide-pretreated samples and only moderate growth recovery for the 25 µM peptide-pretreated samples (Fig. 2b) . These growth recoveries did not change up to 24 h later.
Additional peptide treatment mitigates recovery of peptide-pretreated C. rodentium When peptide-pretreated C. rodentium are permitted to recover for 24 h and are then exposed to a second treatment with peptide, we see no evidence of increased resistance to the second peptide treatment (Fig. 2c) . On the contrary, there is a significant viability loss after the second peptide treatment of peptide-pretreated recovered bacteria. Compared to a 2 log fold decrease in viability after 50 µM peptide treatment of initially untreated bacteria, we see a 3.5 log fold decrease in viability after the same treatment of a 25 µM peptide-pretreated sample. In the case of bacteria initially treated with either 50 or 65 µM peptide, survival after a second treatment with 50 µM peptide falls to below detectable limits of the assay. These data suggest that initial treatment with peptide does not enhance resistance to a second treatment with peptide. 
Peptide pretreatment prevents C. rodentium infection in mouse infection model
Based on results from the in vitro survival assays, we then tested the efficacy of peptide pretreatment on C. rodentium infection in C57BL/6 mice. First, we evaluated safety of the peptide/placebo administration and found that, at the concentrations tested (25-65 µM), there were no changes in the overall health and well-being of mice, and colonic histology was unchanged during the 10 day study. Following the safety studies, the impact of peptide pretreatment on C. rodentium colonization levels was assessed using qPCR with primers to espB of C. rodentium. Results showed significantly elevated levels of C. rodentium in mice infected with either untreated C. rodentium or C. rodentium pretreated with 50 µM placebo (wkhyny) (Fig. 3a) . By contrast, qPCR detected no evidence of C. rodentium in mice infected with peptide-pretreated C. rodentium nor in the mice treated with any of peptide, placebo or sham treatment. It should be noted that the infection dose was standardized to 10 8 c.f.u. after peptide pretreatment as described in Methods. Faecal swab scores confirmed these findings (Fig. S2) . In the mice infected with peptide-pretreated C. rodentium, there were no visible signs of illness, unlike the untreated C. rodentium infected mice and the mice infected with placebo-pretreated C. rodentiumwhere mice were visibly ill with hunched posture, fur ruffling, lethargy and weight loss. In fact, mice infected with peptide-pretreated C. rodentium were indistinguishable from mice challenged with sham or peptide or placebo with respect to all measures of infection in this study including C. rodentium colonization, faecal swab scores and general visual health. Additional experiments indicated that infection was peptide dose dependent, with 100 % infection at the lower dose of peptide administration (25 µM) and reduced infection rates with the higher peptide dose pretreatments (Table S2 ).
Colonic epithelial cell hyperplasia was measured in sections of distal colon stained with haematoxylin and eosin (representative images are shown in Fig. 3b ). As expected, crypt cell length of C. rodentium-infected mice was significantly higher than that in sham-challenged mice (P<0.05) (Fig. 3c) . Similarly, the crypt cell length of mice infected with placebo-pretreated C. rodentium was significantly higher than that in sham-challenged mice (P<0.05). In contrast, crypt hyperplasia of mice infected with peptide-pretreated C. rodentium was not significantly different from that of mice challenged with peptide alone or the shamchallenged group (P>0.05), indicating that C. rodentiuminduced colonic epithelial cell hyperplasia was attenuated with peptide pretreatment. These results provide convincing evidence regarding the efficacy of peptide wrwycr in reducing the occurrence of C. rodentium-induced colonic injury in a mouse model of infection.
Peptide pretreatment reduces C. rodentiuminduced alterations in the faecal microbiome Previous reports have clearly demonstrated significant changes in the faecal microbiome in C. rodentium-infected mice including increased levels of Gammaproteobacter and decreased levels of Lactobacillus relative to non infected mice (Assa et al., 2014) . In our study, comparisons of the microbial composition of faecal pellets by qPCR revealed significant changes in the abundance of Gammaproteobacter in both the C. rodentium treatment group and the placebopretreated C. rodentium treatment group relative to the sham treatment group (Fig. 4) . In striking contrast, levels of Gammaproteobacter in the peptide-pretreated C. rodentium treatment group showed no changes relative to the shamchallenged group, indicating that peptide pretreatment ablates C. rodentium-induced changes in the faecal microbiome. Similarly peptide/placebo only treatment groups also showed no changes in levels of Gammaproteobacter, confirming that neither peptide nor placebo treatment alone alters faecal microbiome profiles. While the levels of Lactobacillus in the C. rodentium treatment group and the placebo-pretreated C. rodentium treatment group were lower than the other treatment groups, there were no significant differences. Finally, as expected, there were no significant differences in the ratios of Bacteriodetes : Firmicutes in any of the treatment groups, a finding that is also consistent with previous reports (Assa et al., 2014) . 
DISCUSSION
This is the first study to demonstrate the efficacy of an antimicrobial peptide treatment in reducing disease outcome in a C. rodentium murine model of EHEC O157 : H7 infection. Both the in vitro and in vivo data presented in this study indicate that brief pretreatment of C. rodentium with wrwycr followed by acid stress decreases bacterial numbers to below the infectious dose of 10 7 c.f.u., hence, reducing the chance for active infection to occur. The in vitro data clearly show that peptide pretreatment of C. rodentium significantly enhances acid-induced pathogen killing in a doseand time-dependent manner. The in vivo results reveal that pretreatment of C. rodentium with 50-65 µM peptide is sufficient to eliminate evidence of infection based on C. rodentium colonization levels, faecal scores, colonic histology and visual observation of overall animal health. Furthermore, the faecal microbiome as assessed by qPCR showed no difference between the group infected with peptide-pretreated C. rodentium and the sham-infected group, providing further confirmatory evidence of infection prevention. These results confirm and extend our previous findings showing a dose-dependent increase in acidinduced killing of peptide-pretreated EHEC seropathotypes associated with severe human disease (Lino et al., 2011) .
The in vitro data clearly demonstrate that, while peptide or acid treatment alone can reduce C. rodentium survival, it is only the combination of peptide followed by acid treatment that results in a dramatic decrease in survival of C. rodentium. Previous research has demonstrated that the pH of murine gastric fluid ranges from 3.0 to 4.0 (Brenneman et al., 2014; McConnell et al., 2008) . These pH values are low enough to induce significant DNA damage, thereby allowing the peptide wrwycr to inhibit DNA repair. This, in turn, leads to higher levels of bacterial cell death due to the inability to repair the DNA damage inflicted by low acid stress. Alternatively or in addition, the acid stress may be synergistic with the peptide's effect on the membrane and the cell's inability to maintain sufficient bioavailable iron or pH homeostasis, thereby increasing its toxicity to C. rodentium. Regardless of the exact mechanism, it is vital that peptide treatment be combined with acid stress to maximize the effect of the peptide on inhibition of DNA repair. This finding underscores the fact that, at the low doses used in this study, the peptide would be less effective as a PI treatment due to the absence of acute acid stress in the distal colon.
The peptide-acid treatment was most successful in enhancing planktonic C. rodentium cell death. In contrast, it was relatively ineffective against established C. rodentium biofilms. Biofilms have been shown to be more resistant than planktonic cells to many antimicrobial agents, using a combination of physical and chemical barriers to prevent antimicrobial penetration into the biofilm (Mah & O'Toole, 2001) . While this may explain why no increase in bacterial cell death was observed in C. rodentium biofilms after peptide treatment, it is also likely that there are other mechanisms in place in biofilms that cause resistance to peptide treatment, such as slow growth, transition of biofilm cells into a resistance phenotype and alterations of the microenvironment within the biofilm (Mah & O'Toole, 2001; Stewart & Costerton, 2001 ).
The ability of the pathogen to recover from subinhibitory concentrations of an antimicrobial agent is germane to any study of antimicrobials. We found that prolonged treatment of C. rodentium with the peptide alone resulted in either partial or full growth recovery only after 50 h and that recovery was dose dependent, with the high concentrations of peptide showing lower levels of recovery. This finding can be attributed to either the peptide being consumed as more bacteria accumulate in the culture through cell division or the employment of various antimicrobial resistance mechanisms by the pathogen (McManus, 1997; Tenover, 2006) . In contrast, recovery was significantly impaired by peptide pretreatment followed by acid stress, with no recovery evident at the highest peptide concentration tested and relatively limited recovery at the lower concentrations. These observations indicate that, while C. rodentium can recover from peptide pretreatment alone, the ability to recover is strongly compromised by peptide pretreatment followed by acid treatment as revealed by both our in vitro and in vivo studies. Furthermore, when C. rodentium are treated with peptide and allowed to recover over a 24 h period, they are at least equally if not more sensitive, depending on the initial peptide dose, to a second treatment of peptide with no evidence of resistance in the recovered population. These findings suggest that a second course of peptide treatment can mitigate recovery after the first peptide treatment.
Finally, the in vivo studies confirmed that administration of peptide over the range of concentrations used in this study caused no changes in the overall health and well-being of mice over the 10 day study period. Furthermore, colonic histology and faecal microbiome analysis of the peptidetreated mice were unchanged relative to the sham and placebo-treated groups. These findings are consistent with previous reports that show no evidence of cytotoxicity in a variety of human cell lines and murine primary cells exposed to peptide at concentrations below 100 µM (Dey et al., 2013; Su et al., 2010) .
In summary, using both in vitro and in vivo models, we demonstrate that peptide wrwycr pretreatment of C. rodentium followed by acid stress, typical of that encountered during gastric passage, is effective at dramatically reducing pathogen survival and ameliorating infection in a murine model of EHEC O157 : H7 infection by enhancing acidinduced pathogen killing. The effect of peptide treatment on survival of C. rodentium is observed regardless of the bacterial growth phase, and when peptide treatment is followed by acute acid stress, outcomes in the murine infection model are unchanged from the sham-challenged mice. Furthermore, neither peptide administration alone nor peptide-pretreated C. rodentium infection alters the faecal microbiota composition or colonic histology as compared with sham-challenged mice, indicating that, at the peptide doses tested, these markers of gut health are not compromised. Taken together, these findings support a role for the peptide wrwycr as a prevention strategy against infection by enteric pathogens by enhancing the body's natural defence system of gastric acid to compromise bacterial survival prior to intestinal colonization.
